Epelman Slava, Nair Deepu, Downey Ross, Militello Mike, Askari Arman T
Division of Internal Medicine, The Cleveland Clinic, USA.
J Thromb Thrombolysis. 2006 Oct;22(2):151-4. doi: 10.1007/s11239-006-8785-1.
Glycoprotein (GP) IIb/IIIa inhibitors have been shown to reduce morbidity and mortality in patients with acute coronary syndromes undergoing percutaneous coronary interventions (PCI). With their widespread use, there is a growing body of literature describing adverse outcomes, including severe thrombocytopenia. Here we report a case of a 75-year-old man who presented with an ST-elevation myocardial infarction, underwent primary PCI and stenting, and subsequently developed profound thrombocytopenia and thrombosis after eptifibatide administration. This report adds to the literature regarding eptifibatide-induced thrombocytopenia and also raises the possibility of a new syndrome of eptifibatide-induced thrombosis. A case is made to examine available databases for thrombosis after administration of eptifibatide and other GPIIb/IIIa inhibitors.
糖蛋白（GP）IIb/IIIa抑制剂已被证明可降低接受经皮冠状动脉介入治疗（PCI）的急性冠状动脉综合征患者的发病率和死亡率。随着其广泛应用，越来越多的文献描述了包括严重血小板减少症在内的不良后果。在此，我们报告一例75岁男性患者，其因ST段抬高型心肌梗死就诊，接受了直接PCI和支架置入术，随后在给予依替巴肽后出现严重血小板减少症和血栓形成。本报告补充了有关依替巴肽诱导的血小板减少症的文献，同时也提出了依替巴肽诱导的血栓形成这一新综合征的可能性。本文呼吁对依替巴肽及其他GPIIb/IIIa抑制剂给药后血栓形成的现有数据库进行研究。
